Rare coexistence of three novel CDCA7-ALK, FSIP2-ALK, ALK-ERLEC1 fusions in a lung adenocarcinoma patient who responded to Crizotinib

In some occasions, intergenic ALK fusions were identified, whereas one or both breakpoints localized in intergenic regions. However, whether intergenic fusions could retain full coding transcripts and generate chimeric proteins was not clear, causing difficulties in target therapy selection. READ ARTICLE

Lung Cancer DOI: 10.1016/j.lungcan.2020.12.013

Authors: Zhao G, Chen L, Xiao M, Yang S.

Real-World OutcomesKirk SmithFebruary 15, 2021coexistence of three ALK fusions, Crizotinib